文拉法辛治疗儿童广泛性焦虑症的研究

目的：评价文拉法辛治疗儿童广泛性焦虑症的临床疗效和不良反应。方法：对76例符合中国精神障碍分类与诊断标准第3版诊断标准的儿童广泛性焦虑症患者，应用文拉法辛及阿普唑仑各38例进行对照治疗。疗程8周。采用汉密尔顿焦虑量表(HAMA)，临床疗效总评量表(CGI)，副反应量表（TESS)评定疗效及不良反应。结果：两种药物的疗效相仿。对精神性焦虑文拉法辛优于阿普唑仑。文拉法辛不良反应少而轻。结论：文拉法辛是治疗儿童广泛性焦虑症安全有效药物。     

RP-HPLC法同时测定血浆中艾司唑仑和阿普唑仑的浓度

目的　建立反相 HPL C法同时测定血浆中艾司唑仑 (EZ)和阿普唑仑 (AZ)浓度的方法。 方法 　以 Techsphere-ODS色谱柱为分析柱 ,甲醇 -水 (65∶ 3 5 )为流动相 ,硝西泮 (NZ)为内标 ,紫外 2 5 4nm处检测。结果 　 EZ和 AZ血浓线性范围为 0 .2 5～ 3 .0μg· ml- 1 ,最低检测浓度分别为 12 .5 ng/ml、12 .5 ng/ml,日内和日间精密度均小于 7%,平均回收率分别为 10 1.5 0 %,96.14 %。 结论 　本法可用于临床血药浓度测定     

帕罗西汀治疗老年人慢性原发性失眠症的临床疗效观察

目的 探讨帕罗西汀治疗老年人慢性原发性失眠症的疗效和安全性。方法 采用随机、单盲、安慰剂、对照方法，将90例老年原发性失眠症患者随机分为帕罗西汀组30例、阿普唑仑组30例和安慰剂组30例，治疗12周。采用匹兹堡睡眠质量指数、临床疗效和治疗药物副作用量表评定疗效和副作用。结果 帕罗西汀组的总有效率为93％，显效率为83％，阿普唑仑组分别为83％和53％，帕罗西汀组显效率高于阿普唑仑组（P＜0．01）。帕罗西汀组常见副作用有口干、便秘、恶心等，不影响治疗。结论 帕罗西汀治疗老年人原发性失眠症疗效确切，副作用轻微。     

马来酸曲美布汀联合阿普唑仑及双歧三联活菌治疗肠易激综合征的临床疗效观察

目的观察马来酸曲美布汀联合阿普唑仑及双歧三联活菌治疗肠易激综合征的临床疗效。方法将120例肠易激综合征患者随机分为观察组与对照组,每组各60例。对照组采用马来酸曲美布汀进行治疗,观察组在对照组的治疗基础上,加用阿普唑仑及双歧三联活菌,两组治疗周期均为4周,治疗结束后评定疗效。结果观察组临床总有效率为90.00%,对照组临床总有效率为63.33%,两组临床疗效差异显著,具有统计学意义(P<0.05)。结论在使用马来酸曲美布汀基础上,加服阿普唑仑及双歧三联活菌治疗肠易激综合征,能显著提高疗效。     

不稳定性心绞痛与情绪障碍

201例不稳定性心绞痛中伴发焦虑、抑郁情绪的共120例,将其随机分为治疗组和对照组,治疗组在常规疗法的基础上加用阿普唑伦治疗。结果表明:不稳定性心绞痛常伴发情绪障碍,对焦虑、抑郁情绪的疗效与不稳定性心绞痛的疗效呈正相关,阿普唑伦是治疗伴发,焦虑、抑郁情绪的一种较为安全、有效药物。     

Chronology of panic and avoidance,age of onset in panic disorder,and prediction of treatment response

Summary The relevance of the chronology between panic disorder and avoidance behavior and of an early, medium or late onset of panic disorder was tested. Groups from the sample of the cross-national collaborative panic study (CNCPS) were compared for differences in basic characteristics and for the ability to predict treatment response. Patients who developed avoidance behavior before the full syndrome of panic disorder had less often a full agoraphobia but were not different in their response to treatment. Patients with an early onset of panic disorder suffered more often from agoraphobia. The treatment response was similar in the groups with early, medium or late onset of panic disorder. Neither the chronology between panic disorder and avoidance behavior nor the age of onset of panic disorder predicted outcome in short-term treatment with alprazolam or impiramine.     

Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam

To assess the effect of itraconazole, a potent inhibitor of cytochrome P450 (CYP) 3A4, on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam, the study was conducted in a double-blind randomized crossover manner with two phases of treatment with itraconazole-placebo or placebo-itraconazole. Ten healthy male subjects receiving itraconazole 200?mg/day or matched placebo orally for 6 days took an oral 0.8?mg dose of alprazolam on day 4 of each treatment phase. Plasma concentration of alprazolam was measured up to 48?h after alprazolam dosing, together with the assessment of psychomotor function by the Digit Symbol Substitution Test, Visual Analog Scale and Udvalg for kliniske undersøgelser side effect rating scale. Itraconazole significantly (P?相似文献   

阿普唑仑治疗功能性消化不良的疗效研究

目的　观察功能性消化不良 (FD)患者 ,在使用抑酸剂和促进胃动力药治疗的基础上加用阿普唑仑后的疗效及对各型FD的疗效。方法　将我院门诊的 1 92例FD患者随机分成两组。实验组 1 2 6例用法莫替丁、吗叮啉、阿普唑仑治疗 ;对照组 66例用法莫替丁、吗叮啉治疗 ;分别观察他们的疗效。并对实验组进行分型 ,观察对各型FD的疗效。结果　实验组总有效率为 86 51 % ,对照组总有效率为 69 70 % ,两组总有效率间的差别有显著性意义 (P <0 0 1 ) ;实验组各分型的疗效间差别有显著性意义 (P <0 0 1 )。结论　在使用抑酸剂和促进胃动力药的基础上加用阿普唑仑治疗FD ,能提高疗效     

盐酸曲唑酮与阿普唑仑治疗成人广泛性焦虑效果比较的Meta分析

目的系统评价盐酸曲唑酮与阿普唑仑治疗成人广泛性焦虑的有效性及安全性。方法计算机检索PubMed（1980～2012．5）、CBM（1990～2012．5）、VIP（1989～2012．5）、CNKI（1990～2012．5）币口Wanfang Data（1990～2012．5）,收集盐酸曲唑酮与阿普唑仑治疗成人广泛性焦虑的随机对照试验,南两名评价者按照纳入与排除标准选择试验、提取资料和评价质量后,采用RevMan5．0软件进行Meta分析。结果纳入5个RCT,共403例广泛性焦虑症患者。Meta分析结果显示：①治疗4周后,盐酸曲唑酮组与阿普唑仑组的HAMA评分和治愈率的差异无统计学意义[RR=I．04,95％CI（0．95,1．13）,P=0．38;RR=I．05,95％CI（0．75,1．48）,P=0．76]。②盐酸曲唑酮组的嗜睡发生率低于阿普哗仑组[RR=0．42,95％CI（0．25,0．72）,P=0．001],但两组在头晕、乏力、食欲减退发生牢方面,差异无统计学意义[RR=0．52,95％CI（0．27,1．01）,P=0．05;RR=0．10,95％CI（0．01,1．41）,P=0．09;RR=2．82,95％CI（0．28,28．23）,P=0．38]。结论盐酸曲唑酮和阿普唑仑治疗广泛性焦虑的疗效无差异,但盐酸曲唑酮不良反应较少,而阿普唑仑更易引起嗜睡。由于纳入研究数量有限且方法学质量不高,本研究结果尚需更多高质量随机对照试验进一步证实。     

Development and validation of a new HPLC analytical method for the determination of alprazolam in tablets

A new analytical method is developed together with its latter validation study, by means of a high resolution liquid chromatography (HPLC) of reverse phase to quantify alprazolam (8-chloro-1-methyl-6-phenyl-4H-[1,2,4] triazole [4,3,-]-[1,4] benzodiazepine) in tablets. Determination is carried out by means of an ODS C18 column (200 mm×4.6 mm i.d., 5 μm particle size); the mobile phase consisted of a mixture of 0.02 M buffer solution of phosphates (pH 6.0) and acetonitrile (45:55, v/v). It is pumped through the chromatographic system at a flow rate of 0.50 ml min⁻¹. The UV detector is operated at 254 nm. The validation study is carried out fulfilling the ICH guidelines in order to prove that the new analytical method, meets the reliability characteristics, and these characteristics show the capacity of an analytical method to keep, throughout the time, the fundamental criteria for validation: selectivity, linearity, precision, accuracy and sensitivity. The method is applied during the working day for the quality control of commercial alprazolam tablets in order to quantify the drug and its degradation products and to check the content uniformity test.